Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Health 340b Program topic
No spam. Unsubscribe anytime.
Committee advances HB 712 to protect 340B program access amid dispute over contract‑pharmacy practices
Summary
HB 712 (HD1), which aims to clarify and protect access to federal 340B discounted drugs for covered entities, passed after testimony from hospitals, health centers and manufacturers that disagreed about contract‑pharmacy practices and program scope.
The committee approved House Bill 712 (HD1), a measure intended to preserve and clarify the state’s approach to the federal 340B drug-discount program for eligible covered entities such as hospitals and federally qualified health centers (FQHCs).
Supporters including The Queen’s Health System, Hawaii Health & Harm Reduction Center, Waianae Coast Comprehensive Health Center and other hospitals and clinics said 340B revenue supports expanded services for underinsured and uninsured patients. “This bill helps really implement and preserve the intent of the 340B program,” a Queen’s representative testified.
Manufacturers and industry groups opposed parts of the bill, arguing growth in contract-pharmacy use and lack of transparency have allowed program practices to deviate from congressional intent. A pharma-industry witness told the committee some members were questioning whether patients receiving discounted drugs through some contract pharmacies were eligible under 340B rules, raising concerns about duplicate discounts and diversion.
Committee action: The committee passed HB 712 with amendments proposed in the hearing record to address transparency and reporting concerns; members said they would continue coordinating with the Attorney General and Department of Health on enforcement mechanisms to ensure eligible patients and covered entities benefit as Congress intended.
Why it matters: Proponents say 340B revenues fund services for low‑income and vulnerable populations; opponents say recent program expansion and contract-pharmacy arrangements warrant additional safeguards to prevent misuse and protect state Medicaid rebate interests.
